Research programme: oncolytic cancer vaccines - Vyriad

Drug Profile

Research programme: oncolytic cancer vaccines - Vyriad

Alternative Names: Vesicular stomatitis virus vaccine - Vyriad; VSV-E6/7 - Vyriad

Latest Information Update: 09 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Omnis Pharma
  • Class Cancer vaccines; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 05 Aug 2016 Vyriad in-licenses STING technology from StingInn
  • 19 Jul 2016 Preclinical trials in Cancer in USA (Parenteral) (Vyraid pipeline, July 2016) before July 2016
  • 18 Mar 2016 Magnis Therapeutics has merged with Omnis Pharma to form Vyriad
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top